Establishment of therapeutic strategy for synchronous double lung cancers based on molecular analysis

基于分子分析的同步双肺癌治疗策略的建立

• 批准号: 23592068
• 负责人: NAGAYASU Takeshi
• 金额: $ 3.33万
• 依托单位: Nagasaki University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011 至 2013
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23592068/
• 关键词: 同時多発肺癌; 肺内転移; 原発多発肺癌; 染色体構造変化; array CGH

We performed molecular analysis of 12 synchronous double lung cancer patients without lymph node metastasis (intrapulmonary metastasis in the same lobe (pm1): n=6, primary: n=6). We then evaluated the clinical outcomes of patients with pathologically diagnosed synchronous double lung cancers (intrapulmonary metastasis (pm): n=80, primary: n=39) and other T3 tumors (n=230). Examination of the concordance rate (CR) of the copy number changes (CNCs) for paired tumors showed that the metastasis group was larger than the primary group (55.5% vs. 19.6%, p=0.04). Pathological diagnosis and molecular classification were the same in 10 out of 12 cases (83%). Both pathological and molecular assessment using aCGH adapted in the current study appeared to have a consistency.

我们对12例无淋巴结转移的同步双侧肺癌患者（同叶肺内转移（pm1）： n=6，原发：n=6）进行了分子分析。然后，我们评估了病理诊断为同步双肺癌（肺内转移（pm）： n=80，原发：n=39）和其他T3肿瘤（n=230）的患者的临床结果。配对肿瘤拷贝数变化（CNCs）的一致性率（CR）显示，转移组大于原发组（55.5% vs. 19.6%, p=0.04）。12例患者中有10例（83%）病理诊断与分子分型相同。在目前的研究中，使用aCGH进行病理和分子评估似乎具有一致性。